

Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of the groups n = 5

EQA round: AP2/21 - Antithrombotic Agents

Deadline: 17.09.2021

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
Set 1														
(108) Apixaban					30							30	26	87%
Samples and groups		[µg/L]												
Sample A1						CVP	266	11	25%	199	333	30	29	97%
(38) IL		266	26	9,6	30							9		
(94) Stago		287	5,0	1,8	9							6		
(193) HYPHEN BioMed		271	17	6,3	6							10		
Other		246	25	10	10							5		
					5							5		
						3x 149, 2x 179								
Sample B1		65,5	6,4	9,8	30	CVP	65,5	2,9	25%	49,1	81,9	30	26	87%
(38) IL		69,7	0,96	1,4	9							9		
(94) Stago		67,5	5,2	7,7	6							6		
(193) HYPHEN BioMed		61,2	9,8	16	10							10		
Other					5							5		
						3x 149, 2x 179								
Set 2														
(109) Dabigatran					33							33	30	91%
Samples and groups		[µg/L]												
Sample A2						CVP	206	10	25%	154	258	33	32	97%
(38) IL		206	24	12	33							11		
(149) Siemens (Dade, BN, Dimension)		199	25	13	11							6		
(193) HYPHEN BioMed		194	13	6,5	6							12		
Other		223	18	8,1	12							4		
					4							4		
						1x 94, 3x 179								
Sample B2		50,3	5,1	10	33	CVP	50,3	2,2	25%	37,7	62,9	33	30	91%
(38) IL		50,3	3,2	6,3	11							11		
(149) Siemens (Dade, BN, Dimension)		49,5	3,7	7,5	6							6		
(193) HYPHEN BioMed		54,3	8,7	16	12							12		
Other					4							4		
						1x 94, 3x 179								
Set 3														
(110) Rivaroxaban					37							37	34	92%
Samples and groups		[µg/L]												
Sample A3						CVP	313	11	25%	234	392	37	36	97%
(38) IL		313	27	8,7	37							11		
(94) Stago		281	11	4,0	11							6		
(193) HYPHEN BioMed		317	14	4,5	6							14		
Other		332	9,9	3,0	14							6		
					6							6		
						2x 149, 1x 162, 3x 179								
Sample B3		73,1	5,3	7,3	37	CVP	73,1	2,2	25%	54,8	91,4	37	34	92%
(38) IL		72,7	3,8	5,2	11							11		
(94) Stago		70,5	2,2	3,2	6							6		
(193) HYPHEN BioMed		74,5	4,8	6,5	14							14		
Other					6							6		
						2x 149, 1x 162, 3x 179								

st_kn_p

End of report

Printed: 30.09.2021